This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CFRX ContraFect (CFRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About ContraFect Stock (NASDAQ:CFRX) 30 days 90 days 365 days Advanced Chart Get ContraFect alerts:Sign Up Key Stats Today's Range$0.05▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.04▼$13.02Volume910,216 shsAverage Volume1.39 million shsMarket Capitalization$535 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus. The company also developing CF-370, an investigational anti-bacterial therapeutic candidate, which is in Phase 1 clinical trials to treat pseudomonas aeruginosa infections, such as ventilator associated pneumonia, blood stream infections, complicated urinary tract infections, and surgery carry infections. It also developing CF-296, an osteomyelitis and PJI which is in preclinical trailers for the treatment of joint infections. In addition, the company developing Exebacase for the treatment of persistent bacteremia caused by methicillin-resistant staphylococcus aureus in COVID-19 patients. Further, It develops CF-296, an engineered lysin, used for treatment of the invasive infections caused by staphylococcus aureus including biofilm-related infections in prosthetic joints and indwelling devices and osteomyelitis. The company has a license agreement with The Rockefeller University to identify novel lysin therapeutic candidates targeting gram-negative pathogens. ContraFect Corporation was incorporated in 2008 and is headquartered in Yonkers, New York. Read More Receive CFRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ContraFect and its competitors with MarketBeat's FREE daily newsletter. Email Address CFRX Stock News Headlines22R.BE,0P0001D9RF,0 (22R.BE)September 22, 2024 | nz.finance.yahoo.comRegenETP, Inc. (RGTPQ)April 16, 2024 | finance.yahoo.comMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.August 26 at 2:00 AM | Brownstone Research (Ad)ContraFect Corp CFRXQJanuary 9, 2024 | morningstar.comMContraFect Corp CFRXNovember 19, 2023 | morningstar.comMContraFect: Q3 Earnings SnapshotNovember 14, 2023 | washingtonpost.comWhy Troika Media Group Shares Are Trading Lower By Over 20%; Here Are 20 Stocks Moving PremarketOctober 23, 2023 | benzinga.comWhy Is ContraFect (CFRX) Stock Up 23% Today?October 16, 2023 | msn.comSee More Headlines CFRX Stock Analysis - Frequently Asked Questions How were ContraFect's earnings last quarter? ContraFect Co. (NASDAQ:CFRX) posted its earnings results on Monday, November, 15th. The biotechnology company reported ($10.40) earnings per share for the quarter, topping analysts' consensus estimates of ($22.64) by $12.24. When did ContraFect's stock split? ContraFect shares reverse split on the morning of Tuesday, February 14th 2023.The 1-80 reverse split was announced on Tuesday, February 14th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. What other stocks do shareholders of ContraFect own? Based on aggregate information from My MarketBeat watchlists, some other companies that ContraFect investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Meta Platforms (META), Tonix Pharmaceuticals (TNXP), Novavax (NVAX), VBI Vaccines (VBIV) and Cidara Therapeutics (CDTX). Company Calendar Last Earnings11/15/2021Today8/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CFRX CIK1478069 Webwww.contrafect.com Phone(914) 207-2300FaxN/AEmployees23Year FoundedN/AProfitability EPS (Trailing Twelve Months)($19.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.15 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-138.70% Debt Debt-to-Equity RatioN/A Current Ratio0.53 Quick Ratio0.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($19.92) per share Price / Book0.00Miscellaneous Outstanding Shares10,700,000Free Float10,639,000Market Cap$535 thousand OptionableNot Optionable Beta0.29 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CFRX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraFect Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraFect With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.